The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia.

The article cites a study which investigates whether the presence of the JAK2 V617F mutation is associated with a higher hemoglobin and increased risk of thrombosis in essential thrombocythemia (ET). Data suggests that the presence of the JAK2 mutation in ET defines a subgroup of patients with both a polycythemic and thrombotic tendency, confirming the results of recent studies. The ease of screening for the V617F mutation makes it a very attractive tool for diagnostic purposes but its role in risk stratification for therapy remains to be further evaluated.